Glioma is one of the common tumors in brain. The expression level of lipoprotein lipase (LPL) or phospholipid transfer protein (PLTP) may influence glioma progression and its relationship with clinical and pathological parameters. The clinical significance of LPL or PLTP expression in glioma has not been established. In the present study, the LPL and PLTP levels in glioma tumors were investigated and the relationship between the LPL and PLTP level and the grade of malignant glioma was analyzed, with the aim to provide new ideas for the diagnosis and treatment of gliomas in clinical and basic research settings. LPL and PLTP mRNA and protein levels were significantly higher in Grade IV glioma than those in the lower grade tumors (P < 0.01). Double immunofluorescent staining showed that the levels of LPL and PLTP were significantly associated with the pathological grade of glioma (P = 0.005). The levels of LPL and PLTP were increased with the shortened survival of glioma patients (P < 0.001). Knockdown of LPL and PLTP led to decreased cell growth and migration but increased apoptosis in vitro. Additionally, cell cycle-related cyclins and their partners were found to be down-regulated while cyclin-dependent kinase inhibitors p16, p21, and Rb were up-regulated. Furthermore, knockdown of LPL or PLTP resulted in the up-regulation of pro-apoptotic molecules and the down-regulation of anti-apoptotic molecules. Ablation of LPL or PLTP in U251 cells resulted in the down-regulation of epithelial mesenchymal transition markers and invasion molecules matrix metalloproteinases. LPL and PLTP appear to be novel gliomaassociated proteins and play a role in the progression of human glioma.
Introduction
Gliomas represent~30% of all brain and central nervous system (CNS) tumors, and 80% of all malignant brain tumors [1] . With the exception of pilocytic astrocytomas, the prognosis of glioma patients is poor. Reportedly, <10% of patients with glioblastoma can live for 5 years after diagnosis, with age at diagnosis and preoperative Karnofsky performance scale being the most well-documented predictors of survival [2] .
Over the past 30 years, the standard treatment for these tumors has evolved to maximal safe surgical resection, radiation therapy, and temozolomide chemotherapy. Although the median survival of patients with glioblastomas has improved from 6 to 14.6 months, these tumors continue to be lethal for the vast majority of patients [3] [4] [5] .
Despite much research advance in understanding the molecular biology of these tumors, effective treatment of these tumors is still difficult. Nearly all patients will have tumor recurrence, and to date, very few therapies have established efficacy as salvage regimens [5] . Therefore, it is important to study the pathogenesis of glioma at the protein level in order to explore new diagnostic and treatment modalities.
Lipoprotein lipase (LPL) is a member of the lipase gene family, which includes pancreatic lipase, hepatic lipase, and endothelial lipase. LPL functions as a homodimer, and has dual functions of triglyceride hydrolase and ligand/bridging factor for receptor-mediated lipoprotein uptake. It also promotes lipid exchange between low density lipoproteins (LDL) (LDL; very LDL, VLDL; chylomicrons) and different high density lipoprotein (HDL) subclasses. Previous studies have shown that LPL and its co-factor, apoC-II, are also expressed in the brain of different mammalian species including humans [6, 7] , and have an impact on fat metabolism balance [8] . It can transport cholesterol across the cell membrane through its function as a molecular bridge. However, the functions of LPL in the CNS are still under investigation [9] .
Phospholipid transfer protein (PLTP) is a widely expressed lipid transfer protein which plays an important role in the plasma lipoprotein metabolism [10, 11] and transfers phospholipids from triglyceride-rich lipoproteins to HDL [12, 13] . Furthermore, PLTP also regulates signal transduction pathways involved in cell survival, apoptosis and inflammation, and it is translocated to the nucleus [14] [15] [16] [17] [18] . It is highly expressed in all types of brain cells [19, 20] .
Lipid, mainly phospholipids and cholesterol, is rich in the CNS. Both LPL and PLTP are involved in lipid metabolism and widely distributed in the brain tissue. The expression of LPL and PLTP in glioma and their relationship with clinical and pathological parameters have not yet been reported. In this study, we evaluated the expression characteristics of LPL and PLTP in different grades of glioma, which provided references for clinical diagnosis and clarified their relationship with the prognosis of glioma patients. Cell growth, colony formation, migration, and apoptosis were also investigated in a tumor cell line in which LPL and PLTP were knocked down to explore the relationship of LPL and PLTP expression with tumor growth, cell migration and apoptosis.
Materials and Methods

Patients and tissue samples
This study was approved by the Ethics Committee of Biomedicine Research, the First Hospital affiliated to the Medical School of Xi'an Jiaotong University (Xi'an, China). Sixty patients were enrolled, who were diagnosed with glioma and treated between June, 2011 to and June, 2014 at the First Hospital affiliated to the Medical School of Xi'an Jiaotong University. All patients were treatment-naïve initial cases who were not preoperatively treated with chemotherapy or radiotherapy. All cases were classified according to the 2007 World Health Organization classification for histological grading of the CNS tumors ( Table 1 ). All pathological diagnoses were confirmed by two or more experienced pathologists who analyzed the samples at the same time, and brain tissue samples from 10 patients with craniocerebral injury or cerebral hemorrhage after decompression were used as control samples.
Antibodies
Mouse monoclonal anti-LPL antibody and rabbit polyclonal anti-PLTP antibody were provided by Drs John Brunzell and John Albers (University of Washington, Seattle, USA). Antibodies against BCL-2, Rb, CDK1, CDK2, Survivin, AIF, APAF1, N-cadherin, Vimentin, MMP2, MMP9, and SNAIL were purchased from Cell Signaling Technology (Danvers, USA). Antibodies against p16, p21, Cyclin B1, Cyclin D1, Cyclin E, CDK4, CDK6, BAD, BAK, BID, PUMA, NOXA, Bcl-xL, and cIAP2 were purchased from Santa Cruz Biotechnology (Santa Cruz, USA). The anti-β-actin antibody was from Boster (Wuhan, China).
RT-PCR analysis of LPL and PLTP
Total RNA from glioma tissues was extracted using Trizol reagent (Invitrogen, Carlsbad, USA), and reverse transcribed according to standard protocols using PrimeScript™ RT reagent kit with gDNA Eraser (TaKaRa, Dalian, China). cDNA amplification was monitored using BRYT green chemistry (Go Taq qPCR Master Mix; Promega, Madison, USA) on an ABI 7500 fast real-time PCR system (Applied Biosystems, Foster City, USA). Sequence of primers were as follows: LPL forward 5′-GGACTTGGAGATGTGGACCA-3′ and reverse 5′-TGCTGCTTCTTTTGGCTCTG-3′; PLTP forward 5′-TCTGAAGACCATGCTGCAGA-3′ and reverse 5′-AGGCCGG TTCTTCTCAATCA-3′. β-Actin was used as an endogenous control with the following primer sequence: forward 5′-GACTACCTCATG AAGATCCTCACC-3′, and reverse 5′-TCTCCTTAATGTCACG CACGATT-3′. All primers were synthesized by AuGCT DNA-SYN (Biotechnology Synthesis Lab., Beijing, China). After 40 cycles, data reduction was performed with Sequence Detection System Software (Applied Biosystems). The fold-changes were calculated via relative quantification (2
−ΔΔCt
).
Western blot analysis
LPL and PLTP were detected in brain tissue homogenates from control and glioma patients by western blot analysis. Samples were lysed on ice for 30 min with radio-immunoprecipitation assay (RIPA) lysis buffer containing HALT phosphatase and protease The fluorescent staining protocol omitted endogenous peroxidase quenching and the concentration of primary antibodies (anti-LPL and anti-PLTP) was increased (1:100). No amplification of the signal was required, and slides were incubated with fluorescently labeled Alexa Fluor 488 (chicken anti-mouse) and 647 (goat anti-rabbit) antibodies (1:200) for 30 min at room temperature. Slides were mounted using anti-Fade mounting medium with DAPI, and micrographs were taken using Nikon TiE microscope, Coolsnap ES 2 camera and merged using NIS Elements software (Nikon, Tokyo, Japan).
Evaluation of IHC
All IHC slides were independently and blindly assessed and scored by two pathologists. The staining scores for LPL and PLTP were assessed semi-quantitatively according to the percentage of positive staining and the staining intensity. An unequivocal positive reaction was defined as a brown signal in the cytoplasm. The staining intensity was scored as 0 (no staining), 1 (weak staining shown as light yellow), 2 (moderate staining shown as yellow brown), and 3 (strong staining shown as brown). The percentage of positive staining was scored as (i) ≤10%; (ii) 11%-50%; (iii) 51%-80%; and (iv) ≥81%. The positive grade score (range: 0-12) was calculated as the product of the staining intensity and percentage score, and scored as 0 (−), 1-4 (+), 5-8 (++), and 9-12 (+++). The positive grade score was the average of two scores as assessed by the pathologists. For statistical evaluation, the expression of LPL or PLTP was classified as negative or low when the staining score was 4, and as positive or high when the staining score was >4.
Knockdown of LPL and PLTP
Small interfering RNA (siRNA) was used to knockdown LPL and PLTP genes. The LPL, PLTP and negative control siRNA duplexes were synthesized by Shanghai GenePharma (Shanghai, China). The following oligonucleotides were used in this study: LPL-872: 5′-GCAGGAAGUCUGACCAAUATT-3′; LPL-1242: 5′-GCAGUUCC AAGGAAGCCUUTT-3′; LPL-1745: 5′-CCUGCGGUAUUUGUG AAAUTTT-3′; PLTP-930: 5′-GCUUGUUGGCAUUGACUAUTT-3′; PLTP-1211: 5′-CCACCUACUUUGGGAGCAUTT-3′; PLTP-1472: 5′-GGUUCCGAAUCUAUUCCAATT-3′; and negative control (Scramble): 5′-UUCUCCGAACGUGUCACGUTT-3′. Transfection of siRNAs into U251 cells [U251 cells derived from a malignant glioblastoma tumor of human brain by explant technique, cultured in DMEM + 10% fetal bovine serum (FBS) and humidified with 5% CO 2 at 37°C.] was carried out using Lipofectamine 2000 (Invitrogen, Carlsbad, USA) in a six-well plate. Cell lysates were prepared for western blot analysis 48 h after transfection. U251 cells treated with transfection reagent alone were included as mock control. The transfection rate was determined to be 80%-90%.
Measurement of cell viability
U251 cells were plated at about 5 × 10 3 cells per well in 96-well culture plates 24 h after transfection. The viability was determined by the methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay. MTT (Sigma-Aldrich, St Louis, USA) solution (0.5 mg/ml, final concentration) was added to each well and incubated for 4 h at 37°C. The supernatant was then removed, and the formazan crystals were dissolved with dimethyl sulfoxide (DMSO). The amount of MTT formazan product was determined with a microplate reader (TECAN, Seestrasse, USA) at the wavelength of 560 nm. The experiments were repeated twice in triplicate.
Colony formation assay
U251 cells were transfected with scrambled or LPL and PLTP siRNA. After 48 h of culture, cells were seeded in 6-well plates at three different cell densities (300, 600, 1200/well) in triplicate. After 10 days of incubation, the plates were stained with crystal violet. Colonies containing more than 50 cells were manually counted. Each experiment was repeated twice in triplicate.
AnnexinV-FITC/PI staining U251 cells were transfected with scrambled or LPL and PLTP siRNA. After 48 h of culture, cells were stained with annexin V using annexinV-FITC/PI apoptosis detection kit (Vazyme, Nanjing, China). Staining was performed according to the manufacturer's instructions. Then cells were analyzed with a flow cytometer (FACSCalibur TM ; BD Biosciences, Franklin Lakes, USA). Data acquisition and analysis was carried out using BD Cell QuestPro software (BD Biosciences).
Cell invasion assay
The invasive ability of LPL-or PLTP-knockdown cells were measured in 24-well transwell chambers (Corning, Corning, USA). The polycarbonate filters containing 8-µm pores were coated on ice with 80 µl of Matrigel (Sigma-Aldrich) at 5 mg/l, and blocked with 1% bovine serum albumin (BSA) for 1 h at 37°C before use. U251 cells were transfected with scrambled or LPL and PLTP siRNA. After 48 h of culture, cells were suspended in serum-free culture medium, and 100 µl (5 × 10 4 cells) were added into the upper compartments of a transwell chamber. In each lower chamber, 600 µl of medium (containing 5% FBS) was added. After 12 h of incubation, the cells from the upper compartment of the filter were removed with a cotton swab, and the cells on the lower surface of the filter were fixed in ethanol and stained with crystal violet. The cells that invaded through the Matrigel and reached the lower surface of the filter were quantified by counting the number of cells that migrated in 10 random microscopic fields per filter under a IX71 microscope (Olympus) at a magnification of ×200.
Scratch assay
U251 cells were seeded in 24-well culture plates at a density of 2 × 10 5 per well in 1 ml Dulbecco modified Eagle medium (DMEM) and incubated for 24 h. A scratch was then made in each well with a sterile pipette tip. The cells were then transfected with scrambled or LPL and PLTP siRNA as described above. Images were captured under a IX71 microscope (Olympus) at ×100 magnification at the beginning of incubation and after 24 h of incubation, The width of a scratch was measured at five different points in each image using Adobe Illustrator software (Adobe, Hills, USA). Cell migration was calculated as the percentage of the width of the scratch at t = 24 h to the width of the scratch at t = 0 h. Two wounds and eight images were sampled for each treatment, and experiments were carried out in triplicate.
Statistical analysis
Data were analyzed with SPSS17.0 (SPSS, Chicago, USA) and GraphPad Prism version 5.0 (GraphPad, San Diego, USA). Differences between LPL and PLTP mRNA expression levels were analyzed by Mann-Whitney test. The one-way analysis of variance (ANOVA) was used for the comparison of protein expression based on histological grade of glioma. The Chi-square test was used for comparison of clinical features between the low and high expression groups of LPL and PLTP. Survival curve was plotted by the Kaplan-Meier method and analyzed using the log-rank test. The threshold for statistical significance was set at P < 0.05. Results mRNA and protein levels of LPL and PLTP in different grades of glioma tissues
To determine whether there was a difference in LPL and PLTP expression in different grades of gliomas, the mRNA levels of LPL and PLTP were initially detected and normalized to β-actin. The expression levels of LPL and PLTP mRNA were distinctly increased in Grade IV tissues compared with those in Grade III tissues and low-grade tissues including Grades I and II (P < 0.01; Fig. 1A,B) . LPL and PLTP mRNA expression levels in Grades III and IV glioma tissues were both significantly higher than those in the lowgrade tumors including Grades I and II (P < 0.01). There was also a significant difference in the mRNA level of LPL and PLTP between Grades III and IV tissues (P < 0.01). Western blot analysis similarly showed that LPL and PLTP protein expression levels were increased with ascending pathological grade (Grades III and IV vs. Grades I and II; P < 0.01; Fig. 1C,D) . Notably, the LPL and PLTP mRNA expression levels were significantly positively correlated with the corresponding LPL and PLTP protein levels (r = 0.8, P = 0.01).
Expression characteristics of the LPL and PLTP in different grades of glioma
Morphology analysis was performed to detect cellular localization and the expression of LPL and PLTP in 60 glioma samples. The results of double immunofluorescent staining showed the high expression of LPL and PLTP in the cytoplasm and nucleus of tumor cells (Fig. 2) . In the low-grade gliomas (Grades I and II), LPL-and PLTP-positive staining was mainly in nucleus of glioma tissues, while little was found in the cytoplasm. However, in the high-grade gliomas (Grades III and IV), LPL and PLTP was abundantly distributed in both the nucleus and the cytoplasm of tumor cells. The intensity of LPL and PLTP staining were also evaluated ( Fig. 3A-C) . The intensity of LPL and PLTP in Grades III and IV glioma tissues was significantly increased compared with that in Grades I and II glioma tissues (Fig. 3B,C) . Furthermore, the intensity of LPL and PLTP in Grade IV glioma tissue was much higher than that in any other tumor group (P < 0.05). A positive correlation was also found between the intensity of LPL and PLTP staining (r = 0.778, P = 0.004). These results showed a similar biological localization of LPL and PLTP in glioma tissue samples.
Relationship between LPL and PLTP expression in glioma and clinical diagnosis
Then the association of the cytoplasmic and nuclear expression of LPL and PLTP with various clinical and pathological characteristics of human glioma was further evaluated. Tables 2 and 3 showed that there was no significant association between LPL and PLTP mRNA expression and other clinical and pathological parameters including gender (P = 0.968 and 0.101, respectively) or age at diagnosis (P = 0.461 and 0.113, respectively). However, the protein levels of LPL and PLTP in the cytoplasm and in the nucleus were significantly associated with the pathological grade of glioma (P = 0.005). Analyses of LPL-and PLTP-positive cell rate in comparison with glioma clinical pathological level indicated a significant positive correlation between the LPL-and PLTP-positive cell and pathological grade (r = 0.905 and 0.884, respectively, P < 0.05). Analysis of LPL-and PLTP-positive cell rate in comparison with glioma clinical pathological types further showed that the average positive expression rates of LPL and PLTP were 46.8% and 51.8% respectively in astrocyte tumors (n = 44); 41.2% and 46.8% respectively in ependymal tumors (n = 5); 53.8% and 58.7% respectively in oligodendroglial tumors (n = 6). No significant statistical difference was found between the expression rates of LPL and PLTP in these types of tumors (P = 0.296 and 0.718, respectively). However, in medulloblastoma (n = 5), the average positive expression rates of LPL and PLTP were up to 76.4 and 76.8%, respectively, which were significantly higher than those in other types of gliomas (P = 0.013 and 0.008, respectively).
Correlation of LPL and PLTP expression in glioma
Both LPL and PLTP mRNA levels as well as their protein levels were increased with the increase of glioma malignant degree in all 60 cases of human brain glioma specimens. Therefore, the relationship between these two proteins was evaluated and results (Table 4) showed that the expression of LPL and PLTP was strongly positively correlated in the human brain gliomas (r = 0.990, P < 0.001).
siRNA decreases LPL and PLTP expression
The siRNAs targeting at LPL and PLTP genes were used to regulate their expression in U251 cells and were subsequently analyzed by western blot analysis. LPL protein was successfully down-regulated in the presence of siRNA LPL-872 and LPL-1242 (Fig. 4A) , and PLTP protein was only successfully down-regulated in the presence of siRNA PLTP-1472 (Fig. 4B) . As expected, the scrambled siRNA did not inhibit the protein expression of LPL or PLTP. Therefore, LPL-1242 and PLTP-1472 were chosen for the subsequent experiments, including cell proliferation, colony formation, cell apoptosis and cell migration.
LPL and PLTP siRNAs inhibit cell growth and colony formation
In cell proliferation assay, knockdown of LPL was shown to inhibit cell growth of U251 cells by 35.89%, 31.37%, and 35.06% at 24, 48, and 72 h, respectively (Fig. 4C) . Similarly, knockdown of PLTP inhibited cell growth by 34.61%, 28.43%, and 31.81% at 24, 48, and 72 h. respectively (Fig. 4C) . Compared with the colony forming ability of scrambled siRNA-transfected U251 cells, the colony forming ability was reduced by 33%-40% (300-1200 cells) in LPL-1242-transfected cells, whereas 34%-39% (300-1200 cells) reduction was observed in PLTP-1472-transfected cells (Fig. 4D ). Significant differences were found between scrambled siRNA group and LPL/PLTP group at 24, 48, and 72 h.
The expression levels of various molecules involved in cellular proliferation, colony formation and during different phases of cell cycle were further measured. It was shown that levels of cyclins (B1, The effects of ablation of LPL and PLTP on apoptosis of U251 cells were investigated using AnnexinV-FITC/PI staining assay. As shown in Fig. 5A , the percentage of apoptotic cells was greatly increased in LPL and PLTP siRNA-transfected U251 cells (14.9% and 15.6%, respectively). More importantly, the apoptosis rate was 18.9% when U251 cells were transfected with both LPL-1242 and PLTP-1472. Subsequently, various anti-apoptotic and pro-apoptotic molecules were investigated in U251 cells transfected with scramble or LPL and PLTP siRNA. Western blotting results showed that proapoptotic molecules including AIF, APAF1, BAD, BAK, BID, PUMA, and NOXA were up-regulated, while anti-apoptotic molecules such as BCL2, Bcl-xL, cIAP2, Axin2, and Survivin were downregulated (Fig. 5B) .
Knockdown of LPL and PLTP genes reduces the cell motility
The effect of LPL and PLTP knockdown on the migration of U251 cells was measured by both scratch assay and invasion assay.
Scratch assay results showed that LPL and PLTP siRNA significantly reduced U251 cell migration after 24 h of incubation. However, scramble siRNA failed to inhibit the U251 cell migration (Fig. 6A) .
Cell invasion assay results showed that knockdown of LPL and PLTP resulted in 57.14% and 53.42% decrease in migration ability of U251 cells respectively (Fig. 6B) . Subsequently, the role of various signaling pathways that contribute to cell migration was investigated. It was found that the expressions of mesenchymal transition markers, such as N-cadherin, Vimentin and SNAIL, were downregulated (Fig. 6C) . Furthermore, there was a significant decrease at the level of invasion molecules, such as matrix metalloproteinase 2 (MMP2) and MMP9,when LPL and PLTP were inhibited (Fig. 6C ).
Discussion
It is well known that lipid mobilization is of great importance for tumor growth, and previous studies have suggested that cancer cells exhibit abnormal cholesterol and phospholipid metabolism [21] [22] [23] . Both LPL and PLTP play a central role in lipid metabolism [11, 24, 25] . In the present study, we found that both LPL and PLTP are positive in tumor cells, and that the higher grade of glioma correlates with the number of LPL-and PLTP-positive cells. Previous studies have revealed that LPL is one of the lipidrelated predictors of shorter patient survival in some types of cancers, such as non-small cell lung carcinoma, chronic lymphocytic leukemia, and breast carcinoma [26] [27] [28] reported that PLTP is differentially expressed in multiple types of tumors, including prostate, ovarian, breast and lung carcinoma [29] [30] [31] [32] . Through online data mining, Ferkingstad et al. [33] implicated that PLTP is the main component in one of the nine pathways that regulate survival in breast cancer. Overexpression of LPL and PLTP protein has been found in different types of tumors [26, 27, [30] [31] [32] 34] . However, the effects of LPL and PLTP on the biological behavior of glioma cells have not been reported. In the present study, knockdown of LPL and PLTP was found to be correlated with decreased cell proliferation and colony formation of U251 cells, indicating that the up-regulation of LPL and PLTP in glioma cells might regulate glioma cell proliferation and migration. LPL and PLTP might play an important role in tumor cell apoptosis because the percentage of apoptosis cells transfected with LPL and PLTP siRNA was found to be increased when compared with cells transfected with scrambled siRNA. Cell cycle is regulated by various molecular events which are altered during tumor growth. CDK-Cyclin complexes are closely associated with cell cycle phases. In the present study, we identified that knockdown of LPL or PLTP gene expression in U251 cells resulted in the alteration of key molecules involved in various cell cycle phases. Cyclin B1, Cyclin D1, Cyclin E and their partners CDK1, CDK2, CDK4, and CDK6 were down-regulated. Furthermore, it was shown that Cyclin-dependent kinase inhibitors (CKIs), such as p16, p21, and Rb, were also up-regulated. These results suggest that LPL and PLTP ablation is associated with cell cycle arrest and inhibition of cell proliferation of U251 cells.
Knockdown of LPL and PLTP was found to result in the upregulation of pro-apoptotic molecules AIF, APAF1, BAD, BAK, BID, PUMA, and NOXA. Furthermore, anti-apoptotic molecules, such as BCL-2, Bcl-xL, cIAP2, Axin2, and Survivin, were downregulated in the LPL or PLTP knockdown U251 cells, indicating that LPL and PLTP may be potential therapeutic targets in glioma treatment.
Activation of the epithelial mesenchymal transition (EMT) program has been proposed as the critical mechanism for the acquisition of malignant phenotypes in various types of cancer cells [35] [36] [37] . There was evidence demonstrating that primary glioblastoma and its stem cell lines express cellular and molecular characteristics of mesenchymal stem cells [38] . It had been indicated that EMT might be an ideal target for cancer therapy not only in epithelial cancer cells, but also in glioblastomas [39] . Interestingly, knockdown of LPL or PLTP resulted in downregulation of EMT molecules including N-cadherin, Vimentin and SNAIL, as well as the invasion molecules MMP2 and MMP9. These effects may contribute to the anti-migration and antiinvasion potential of ablation of LPL and PLTP in human glioblastoma cells.
To our knowledge, this is the first study to determine and report the expression patterns, clinical significance and functions of LPL and PLTP at transcriptional and translational levels in glioma tissues. Our results suggest that LPL and PLTP may be valuable biomarkers in diagnosing malignant degree of glioma and evaluating patient prognosis after surgery. LPL and PLTP may also play a role in the progression of human glioma and may be potential new clinical therapeutic targets for human glioma.
